FDA
-
-
-
-
-
-
-
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome
-
-
-
-
-
-
-
Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September
-
-
-
-
-
-
-
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
-
-
-
-
-
-
Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results
-
-
-
-
-
-
-
TFF Pharmaceuticals Inc. (TFFP) Reports Q4, Provides Business Update
-
-
-
-
-
-
322,220 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

